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Early diagnosis of lung cancer is important due to high mortality in late stages of
the disease. An ideal approach for population screening could be the breath
analysis, due to its non-invasiveness, simplicity and cheapness. Using sensitive
methods of analysis like gas chromatography/mass spectrometry in exhaled air of
cancer patients were discovered some volatile organic compounds – possible
candidates for cancer markers. However, these compounds were not specific for
cancer cells. At the same time, integrative approaches used to analyze the exhaled
breath have demonstrated high sensitivity and specificity of this method for lung
cancer diagnosis. Such integrative approaches include detection of smell prints by
electronic nose or integrated analysis of wide range of volatile organic compounds
detected by gas chromatography/mass spectrometry or related methods. Modern
statistical pattern recognition systems like logistic regression analysis, support
vector machine or analysis by artificial neuronal network may improve diagnostic
accuracy.
Lung cancer is the most common cancer
worldwide. The diagnosis of early stage
lung cancer is essential and substantially
determines the life expectancy. Five-year
survival is expected in 58–73% of
patients with stage I lung cancer. For
later stages of disease the 5-year survival
rate is only 3.5%. Unfortunately, only
15% of lung cancer cases are diagnosed
at an early stage. Over half of people
with lung cancer die within the first year
of being diagnosed [1].
The problem is that available diagnos-
tic methods, that is, sputum cytological
analysis and chest x-ray, are not sensitive
enough, and they are expensive or inva-
sive. They do not fit well for population
screening [2,3]. An ideal approach could
be breath analysis due to its non-inva-
siveness, simplicity and cheapness. It is
especially suited for lung cancer screen-
ing and monitoring as other methods
like computerized tomography are
expensive and cannot be applied as fre-
quently as necessary due to irradiation.
Integrative approaches used to analyze
the exhaled breath have demonstrated
high sensitivity and specificity of this
method for lung cancer diagnosis. Such
integrative approaches include detection
of breathprint by electronic nose or inte-
grated analysis of wide range of volatile
organic compounds (VOCs) detected by
gas chromatography/mass spectrometry
or related methods [4–6].
At the same time, attempts to identify
particular compounds specific for lung
cancer have not been successful up to
present time. Several laboratories have
tried to select specific cancer markers
from the headspace of cancer cell cul-
tures. Some of the compounds selected
were alcanes or methylated alcanes
like decane, nonadecane, eicosane [7],
2-methylpentane, spirits like 2-ethyl-
1-hexanol and ketones like 2-pentadeca-
none [8]. One problem with headspace
measurements of cell cultures is that the
cells take up the chemical compounds
from the medium, metabolize them and
then release the products of the metabo-
lism. Thus, the product of cells is
dependent on the environment in which
cells are located. Besides, different tumor
cell types in the same medium metabolize
different compounds and release distinct
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VOCs [9]. And finally, these data do not prove that tumor cells
are the exclusive source of mentioned putative cancer markers.
Another approach is to select specific VOCs from the
exhaled air of lung cancer patients. Relevant studies have shown
that some compounds in the breath of cancer patients are
present in elevated, but some in diminished concentrations,
when compared with healthy controls. However, no specific
compounds characteristic exclusively for cancer cells have ever
been found. In these studies, the question remains, what is the
source of VOCs in the exhaled air? Is the amount of VOCs
released from the tumor cells in the exhaled air sufficient to
meet the detection limit of the method used? Previous studies
have examined the exhaled air composed of dead space and
alveolar fractions. VOCs originating from lung tumors are
expected to be present in dead space fraction. Alveolar fraction
is expected to contain VOCs from blood circulation, released
by different body cells, including the tumor cells of the lung.
In mixed exhaled air, the content of VOCs released by lung
tumor cells may be low and may not exceed the detection
limit. At the same time, the alveolar air may contain VOCs
released by tumors from any location.
Apart from VOCs, tumor cells produce wide range of cyto-
kines like IL-4, IL-6, IL-11, IL-15, TNF-a, TGF-b and others,
which activate body’s immune system and change the metabo-
lism of wide range of body cells [10,11]. An example of cancer
influence on the body is cachexia, which is characterized by
hypermetabolism and generalized muscle wasting. Recently, a
cytokine responsible for these changes was discovered – it is a
TNF-like weak inducer of apoptosis. TNF-like weak inducer of
apoptosis activates various proteolytic pathways and stimulates
the degradation of myofibril proteins [12].
Interesting is the observation of Poli et al. [13], who measured
a set of VOCs in exhaled air before and 4 weeks after the
tumor resection. VOCs present in elevated concentrations
before the surgery remained at the same level after the resec-
tion. The only exception was isoprene, the concentration
levels of which dropped to the level of healthy controls.
Re-examination of the same subjects 3 years later showed that
only after this time period such VOCs as pentane, benzene,
ethylbenzene and toluene have returned to the levels observed
in controls [14]. Authors concluded “that exhaled VOCs do not,
or only in part, derive from cancerogenous tissue, being their
concentration is unaffected by surgical removal … A possible
explanation of these data is that exhaled VOCs cannot be con-
sidered biomarkers of lung cancer per se, rather epiphenome-
non which accompany lung cancer development…” [14].
However, the pathogenesis of this epiphenomenon is still
unclear. Persistence of elevated levels of VOCs in exhaled air
even 1 month after the removal of tumor cannot be explained
by substances produced by the tumor itself. Evidently during
the process of cancerogenesis some longstanding changes
develop also outside the tumor. These changes may be of
immunological or genetic origin. Based on observations that
VOCs pattern did not differ between the tumor stages,
Phillips et al. postulated the mechanism by which polymorphic
isoforms of cytochrome P450 family enzymes are formed in
the early stages of cancerogenesis. These enzymes oxidize DNA
to induce cancerogenic mutations and oxidize membrane phos-
pholipids with production of alcanes and methylated alcanes,
which are exhaled with breath [15].
Whatever is the intimate mechanism of VOCs production, it
is clear that in cancerous state their concentrations in exhaled
air become changed in a typical manner, which may be uncov-
ered by large-scale analysis.
Applicable for such a purpose is electronic nose. Diagnostics
using this device is simple, sufficiently accurate, inexpensive,
non-invasive, allows online diagnosis and can differentiate het-
erogeneous disorders. The information provided by this techni-
que is not based on detecting single and separate molecular
signals, but is exclusively derived from pattern recognition
among an array of signals by using powerful bioinformatics [16].
Electronic nose is an instrument made up of different kind
of chemical sensors combined with a pattern recognition
system. The measurement in electronic nose is based on the
different mechanisms – electrical resistance, ion-gas or colori-
metric sensor response that differs regarding VOCs molecular
pattern [17]. If there has been no change in the composition of
the air, the resistance of sensors does not change. When sensors
are exposed to VOCs, they absorb the analyte and subsequently
change their electric resistance. Each sensor may give response
to different VOCs. At the same time, several sensors may react
with the same VOC. A unique response curve combination is
recorded, containing the information to allow discrimination
of the different samples. If we examine patient groups with
different diseases, pattern recognition system develops typical
average ‘breathprint’ characteristic for patients with similar
diagnosis [16].
Clinical studies have shown potential of exhaled breath anal-
ysis by electronic nose. Machado et al. in their study found
that exhaled air analysis demonstrated discrimination between
samples from patients with lung cancer and those from other
groups. In the validation study, the electronic nose had 71.4%
sensitivity and 91.9% specificity for detection of lung cancer.
Positive and negative predictive values were 66.6 and 93.4%,
respectively [18].
Dragonieri et al. in two studies demonstrated that VOC pat-
terns of exhaled breath discriminates patients with lung cancer
from chronic obstructive lung disease (COPD) patients, as well
as healthy controls and malignant pleural mesothelioma from
subjects with similar occupational asbestos exposure without
malignant pleural mesothelioma, and from healthy controls. In
all three studies, the conclusion was that the electronic nose
may qualify as a non-invasive diagnostic or screening tool for
lung malignancy in the future [19,20].
In other study, the breath of volunteers was examined by a
tailor-made array of cross-reactive nanosensors based on organi-
cally functionalized gold nanoparticles and gas chromatography
linked to the mass spectrometry. The results showed that the
gold nanosensor array could differentiate between ‘healthy’ and
‘cancerous’ breath, and, furthermore, between the breath of
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patients having different cancer types – lung, breast, colorectal
or prostate cancer. The gas chromatography/mass spectrometry
results showed that each cancer could have a unique pattern of
VOCs, when compared with healthy states, but not when com-
pared with other cancer types [21].
A significant challenge to exhaled breath analysis by electronic
nose is posed by the heterogeneity of patients. Both lung cancer
and COPD are diseases associated with cigarette smoking, and
both coexist in many patients. In many patients, advanced lung
cancer is comorbid with complications like post-obstructive ate-
lectasis, pneumonia, exudative pleuritis or carcinomatous lym-
phanghoitis, which can significantly change the VOCs pattern
in exhaled breath. Finally, patient smoking status, smoking his-
tory and even diet may confound prognostic results of analysis.
Evidence that discrimination is possible comes from studies
trying to differentiate patients with combined diseases, for
example, lung cancer and COPD. Two hundred and eleven
out of 221 (95.5%) lung cancer patients were classified cor-
rectly in a study population consisting of patients with lung
cancer alone, COPD alone, lung cancer with concomitant
COPD and healthy volunteers. The main classification error
occurred between cancer and cancer COPD group, which is
not clinically significant [22].
Development of specific mathematical models for diagnosis
of lung cancer using exhaled breath by electronic nose may
improve diagnostic accuracy. In all studies mentioned above,
the principal component or canonical discriminant analyses
were used for predictive purposes. Modern statistical pattern
recognition systems offer an opportunity to choose methods
with potentially best predictive value, for example, logistic
regression analysis, support vector machine or even artificial
neuronal network approach [23].
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